Evolent Health, Inc. Financial Ratios
EVH|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-15.6%
Profit Margin
-13.4%
Net Income / Revenue
Asset Turnover
0.25
Revenue / Total Assets
Equity Multiplier
4.57
Total Assets / Equity
Composite: -15.6% (reported: -15.6%)
Profitability
Liquidity
Current Ratio
1.31
Quick Ratio
1.31
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.25
Inventory Turnover
-
Days Sales Outstanding
234 days
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
Earnings Quality
Accrual Ratio
-4.7%
-1.5pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.